Bone Therapeutics
Clinical-stage biotechnology company developing cell- and biologic-based regenerative therapies to accelerate bone healing, reduce surgical complications, and support hospital adoption. Activities include translational research, preclinical studies, and clinical trials with peer-reviewed publications and institutional collaborations.
Industries
Nr. of Employees
medium (51-250)
Patents
Formulations involving solvent/detergent-treated plasma (S/D plasma) and uses thereof
US-11458166-B2
View Details
Formulations involving solvent/detergent-treated plasma (S/D plasma) and uses thereof
US-11458166-B2
View DetailsProducts
BT-101
Allogeneic cell therapy candidate intended to accelerate bone consolidation and reduce the need for additional interventions in fracture non-union.
BT-202
Combination biologic program designed to improve spinal fusion outcomes and reduce recovery time.
BT-303
Regenerative strategy using scaffolds and growth factors for segmental bone loss and defect repair; listed as a clinical candidate.
BT-101
Allogeneic cell therapy candidate intended to accelerate bone consolidation and reduce the need for additional interventions in fracture non-union.
BT-202
Combination biologic program designed to improve spinal fusion outcomes and reduce recovery time.
BT-303
Regenerative strategy using scaffolds and growth factors for segmental bone loss and defect repair; listed as a clinical candidate.
Expertise Areas
- Regenerative medicine for bone
- Allogeneic cell therapy development
- Combination biologics
- Biomaterials and scaffold engineering
Key Technologies
- Allogeneic cell therapy
- Combination biologics
- Biomaterial scaffolds
- Growth-factor delivery
News & Updates
Peer-reviewed publication reporting preclinical results that showed increased bone formation in a large-animal model.
Phase I study reporting safety and tolerability results for BT-101.
Conference poster presenting evaluation of biomarkers in patients treated with the company's therapy.
Peer-reviewed publication reporting preclinical results that showed increased bone formation in a large-animal model.
Phase I study reporting safety and tolerability results for BT-101.
Conference poster presenting evaluation of biomarkers in patients treated with the company's therapy.